GlassScriptPhysician profile
Olivia D Martinez
NPI 1629490362
$10,975.75
in general payments reported to CMS, 2019-2025
28 companies · $2,676 in 2025
The $2,676 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,042 · 2022: $1,582 · 2023: $2,742 · 2024: $2,934 · 2025: $2,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,820 · Education: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,819.96 |
| Education | $531.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $2,047.92 | 2021-2025 | Adbry, Anzupgo |
| Abbvie INC. | $1,787.18 | 2021-2025 | |
| Janssen Biotech, INC. | $773.24 | 2021-2025 | Tremfya |
| Ucb, INC. | $706.97 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $680.82 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $508.85 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $461.93 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $459.10 | 2021-2025 | Jublia, Arazlo, Cabtreo |
| Amgen INC. | $451.86 | 2021-2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $433.34 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $381.65 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $376.05 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $363.17 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $303.60 | 2021-2025 | |
| Incyte Corporation | $270.50 | 2022-2025 | Opzelura |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $266.93 | 2023-2025 | Aklief, Nemluvio |
| Dermavant Sciences, INC. | $252.12 | 2023-2024 | Vtama |
| Allergan, INC. | $138.12 | 2021 | |
| Novo Nordisk INC | $60.92 | 2025 | Rybelsus, Ozempic |
| Journey Medical Corporation | $50.40 | 2022 | |
| Sumitomo Pharma America, INC. | $43.79 | 2024-2025 | Gemtesa |
| Organon LLC | $42.31 | 2025 | Vtama |
| Organogenesis INC. | $24.88 | 2024 | Puraply Am |
| Botanix Sb INC | $24.18 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $21.11 | 2021 | |
| Strata Skin Sciences, INC. | $19.49 | 2023 | Xtrac |
| Janssen Scientific Affairs, LLC | $12.81 | 2025 | Tremfya |
| Biofrontera INC. | $12.51 | 2024 | Rhodoled Xl, Ameluz, Xepi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.